" Marvel Biosciences (TSXV:MRVL) asset shows a reduction in liver fibrosis in multiple pre-clinical models

Marvel Biosciences Corp. (MRVL) and its wholly-owned subsidiary, Marvel Biotechnology Inc.has found its lead asset, MB-204 was active in two different pre-clinical models.

" Marvel Biosciences (TSXV:MRVL) updates the status of its MB-204 manufacturing efforts

Marvel Biosciences Corp. (MRVL) reports a successful process development of the active pharmaceutical ingredient of its lead drug MB-204.